Back to Search
Start Over
A proof of concept for structure-based vaccine design targeting RSV in humans.
- Source :
-
Science (New York, N.Y.) [Science] 2019 Aug 02; Vol. 365 (6452), pp. 505-509. - Publication Year :
- 2019
-
Abstract
- Technologies that define the atomic-level structure of neutralization-sensitive epitopes on viral surface proteins are transforming vaccinology and guiding new vaccine development approaches. Previously, iterative rounds of protein engineering were performed to preserve the prefusion conformation of the respiratory syncytial virus (RSV) fusion (F) glycoprotein, resulting in a stabilized subunit vaccine candidate (DS-Cav1), which showed promising results in mice and macaques. Here, phase I human immunogenicity data reveal a more than 10-fold boost in neutralizing activity in serum from antibodies targeting prefusion-specific surfaces of RSV F. These findings represent a clinical proof of concept for structure-based vaccine design, suggest that development of a successful RSV vaccine will be feasible, and portend an era of precision vaccinology.<br /> (Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
- Subjects :
- Adolescent
Adult
Antibodies, Neutralizing blood
Antibodies, Viral blood
Epitope Mapping
Humans
Middle Aged
Young Adult
Immunogenicity, Vaccine
Respiratory Syncytial Virus Infections prevention & control
Respiratory Syncytial Virus Vaccines chemistry
Respiratory Syncytial Virus Vaccines immunology
Respiratory Syncytial Virus, Human immunology
Viral Fusion Proteins chemistry
Viral Fusion Proteins immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1095-9203
- Volume :
- 365
- Issue :
- 6452
- Database :
- MEDLINE
- Journal :
- Science (New York, N.Y.)
- Publication Type :
- Academic Journal
- Accession number :
- 31371616
- Full Text :
- https://doi.org/10.1126/science.aav9033